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Background: The introduction of the Sensititre® MYCOTB MIC
plate a microtitre plate containing lyophilized antibiotics and con-
ﬁgured for thedeterminationofminimuminhibitory concentration
to ﬁrst and second line anti-tuberculosis drugs can change the
laborious methods currently used for drug susceptibility testing.
At present reputable procedures for susceptibility testing of M.
tuberculosis categorize clinical isolates as either drug resistant
or drug susceptible due to their ability to grow in the presence
of mostly single critical concentration despite of whether high
level, moderate level or low level drug resistance is present. The
limited scientiﬁc background for critical concentrations used for
particularly second-line drugs is especially problematic. The deter-
mination ofM. tuberculosis susceptibility testing usingMICs instead
of useof critical concentrationwill be oneof theﬁrst in SouthAfrica.
However, the performance of the Sensititre plate has not been com-
pared to methods that uses MICs for susceptibility testing the agar
proportion method and Etest.
Objective: To evaluate Sensititre® MYCOTB MIC plate perfor-
mance against agar proportion (APM) and Etest methods
Methods&Materials: Seventy-ﬁveM. tuberculosis isolateswere
included in the study. Isolates were collected from the Drug Resis-
tance survey currently being carried out in South Africa since
2012. The full spectrum of resistance from mono-resistance and
poly-resistance through MDRTB, to pre-XDRTB and XDRTB.were
included in the study. MICs categorical and essential agreements
(± 1dilution from critical concentration) were compared of the
microtitre Sensititre MYCOTB plate method against the agar pro-
portion and the Etest methods.
Results: Essential agreement between Sensititre plate and APM
with respect to susceptible or resistant was 92% for 10 of 11 drugs
and 96% by categorical agreement. For ethambutol, essential agree-
ment was 80-81%. while for moxiﬂoxacin, agreement was 83-85%.
Categorical agreement between Etest and APM methods was 100%
for rifampin, ethambutol, streptomycin, and oﬂoxacin and 98% for
isoniazid. They was a high rate of contamination with Etest which
warranted many repeats. For MYCOTB and Etest, median time to
plate interpretation was 10 days while APM it was 21 days.
Conclusion: The Sensititre method provides a more rapid,
quantitative, and efﬁcient method with no test failures due to con-
tamination for both ﬁrst- and second-line drugswhen compared to
the APM and Etest.
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Inﬂuenza: understanding pathogenesis to
improve outcomes
J. McCullers
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Secondary bacterial infections account for a signiﬁcant portion
of excess mortality during seasonal inﬂuenza epidemics. With the
emergence of the H1N1 pandemic strain in 2009 and the ongoing
threat of a new pandemic from highly pathogenic avian H5N1 or
H7N9 strains, prevention and treatment of bacterial complications
has become an important issue for public health planning. Sev-
eral mechanisms underlie the ability of inﬂuenza viruses to prime
the host for secondary bacterial infections. An improved under-
standing of thesemechanisms has allowed development of speciﬁc
therapies. Prevention by vaccination against either the virus or the
super-infecting bacteria is the ﬁrst line of defense. However, vac-
cines are imperfect and may not be available for pandemic strains.
Treatment of the viral infection using a neuraminidase inhibitor
has been shown to both decrease the incidence of secondary
infection and ameliorate the severity of the resulting pneumonia
from secondary bacterial pathogens. The use of protein synthe-
sis inhibitors rather than cell-wall active antibiotics may be the
preferred therapy in the setting of prior inﬂuenza to reduce the
inﬂammatory burst that occurs during bacterial lysis. Modulation
of this immune response with targeted anti-inﬂammatory thera-
pies may also improve outcomes. The basis for these strategies and
a discussion of their potential application to treatment of bacte-
rial infections complicating inﬂuenza will be discussed during the
seminar.
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Impact of acellular and whole cell pertussis
vaccines on disease burden
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Since the late 1940s, pertussis vaccines prepared by forma-
lin inactivation of “whole cell” Bordetella pertussis organisms have
resulted in a marked decline in the rates of pertussis disease.
However, concern for local and systemic reactions resulted in the
identiﬁcation and puriﬁcation of several proteins produced by the
Bordetella pertussis organism. New “acellular vaccines,” formulated
